PAULA KANTAS

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

-Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. -Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies. -Support for the No Surprises Act Enforcement Act (HR 4710), which would increase penalties for health plans and issuers that violate the laws balance billing requirements and establish consequences for failing to make required payments following an IDR determination in a timely manner. -Comments in response to the introduction of the Patients Deserve Price Tags Act (S 2355), which would increase healthcare price transparency requirements among hospitals, insurers and certain healthcare providers.

Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

-Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. -Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies. -Support for the No Surprises Act Enforcement Act (HR 4710), which would increase penalties for health plans and issuers that violate the laws balance billing requirements and establish consequences for failing to make required payments following an IDR determination in a timely manner. -Comments in response to the introduction of the Patients Deserve Price Tags Act (S 2355), which would increase healthcare price transparency requirements among hospitals, insurers and certain healthcare providers.

Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

-Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. -Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies. -Support for the No Surprises Act Enforcement Act (HR 4710), which would increase penalties for health plans and issuers that violate the laws balance billing requirements and establish consequences for failing to make required payments following an IDR determination in a timely manner. -Comments in response to the introduction of the Patients Deserve Price Tags Act (S 2355), which would increase healthcare price transparency requirements among hospitals, insurers and certain healthcare providers.

-Supporting S. 4008, the Promoting Dental Health Act, which would reauthorize the CDC DOH for five years. -urging appropriators to support health infrastructure investment across the U.S. Department of Health and Human Services (HHS) including critical investments in oral health workforce, research, and prevention. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Urging CMS to use its existing authorities to ensure that Medicare Part D plans prioritize and ensure meaningful access to all FDA-approved, evidence-based, non-opioid medicines indicated for acute pain, including newly approved and first-in-class therapies. -Supporting the H-1Bs for Physicians and the Healthcare Workforce Act (HR 7961), which would exempt physicians, dentists and other healthcare workers from the new $100,000 fee for H-1B petitions as well as prohibit new H-1B fees that exceed the existing fees under the U.S. Code from being imposed on healthcare workers. -Urging apppropriators to reject policies that would prohibit or condition the eligibility of publication costs for federally funded research.

-Support for the Patients First Act (HR 9693), which would provide long term reform to the Medicare physician payment system. -Support for H.R. 8500, the Timely Access to Coverage Decisions Act of 2026, which would help to ensure that patients have access to medically necessary items and services by making the Medicare local coverage determination (LCD) process more predictable and meaningful. -Support for the Ensuring Kids Have Access to Medically Necessary Dental Care Act (S 5088/HR 9833), which would strengthen dental coverage under the Childrens Health Insurance Program (CHIP) by prohibiting lifetime and annual dollar limits on dental benefits and requiring dental-only wraparound coverage for certain children.

-Support for the Patients First Act (HR 9693), which would provide long term reform to the Medicare physician payment system. -Support for H.R. 8500, the Timely Access to Coverage Decisions Act of 2026, which would help to ensure that patients have access to medically necessary items and services by making the Medicare local coverage determination (LCD) process more predictable and meaningful. -Support for the Ensuring Kids Have Access to Medically Necessary Dental Care Act (S 5088/HR 9833), which would strengthen dental coverage under the Childrens Health Insurance Program (CHIP) by prohibiting lifetime and annual dollar limits on dental benefits and requiring dental-only wraparound coverage for certain children.

-Support for the Patients First Act (HR 9693), which would provide long term reform to the Medicare physician payment system. -Support for H.R. 8500, the Timely Access to Coverage Decisions Act of 2026, which would help to ensure that patients have access to medically necessary items and services by making the Medicare local coverage determination (LCD) process more predictable and meaningful. -Support for the Ensuring Kids Have Access to Medically Necessary Dental Care Act (S 5088/HR 9833), which would strengthen dental coverage under the Childrens Health Insurance Program (CHIP) by prohibiting lifetime and annual dollar limits on dental benefits and requiring dental-only wraparound coverage for certain children.

Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

-Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. -Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies. -Support for the No Surprises Act Enforcement Act (HR 4710), which would increase penalties for health plans and issuers that violate the laws balance billing requirements and establish consequences for failing to make required payments following an IDR determination in a timely manner. -Comments in response to the introduction of the Patients Deserve Price Tags Act (S 2355), which would increase healthcare price transparency requirements among hospitals, insurers and certain healthcare providers.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

-Support for the Improving Dental Administration Act (HR 7931), which would apply state dental insurance laws to ERISA dental plans operating in that state. -Support for the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies. -Support for the No Surprises Act Enforcement Act (HR 4710), which would increase penalties for health plans and issuers that violate the laws balance billing requirements and establish consequences for failing to make required payments following an IDR determination in a timely manner. -Comments in response to the introduction of the Patients Deserve Price Tags Act (S 2355), which would increase healthcare price transparency requirements among hospitals, insurers and certain healthcare providers.

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

-Supporting S. 4008, the Promoting Dental Health Act, which would reauthorize the CDC DOH for five years. -urging appropriators to support health infrastructure investment across the U.S. Department of Health and Human Services (HHS) including critical investments in oral health workforce, research, and prevention. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Urging CMS to use its existing authorities to ensure that Medicare Part D plans prioritize and ensure meaningful access to all FDA-approved, evidence-based, non-opioid medicines indicated for acute pain, including newly approved and first-in-class therapies. -Supporting the H-1Bs for Physicians and the Healthcare Workforce Act (HR 7961), which would exempt physicians, dentists and other healthcare workers from the new $100,000 fee for H-1B petitions as well as prohibit new H-1B fees that exceed the existing fees under the U.S. Code from being imposed on healthcare workers. -Urging apppropriators to reject policies that would prohibit or condition the eligibility of publication costs for federally funded research.

-Support for the Patients First Act (HR 9693), which would provide long term reform to the Medicare physician payment system. -Support for H.R. 8500, the Timely Access to Coverage Decisions Act of 2026, which would help to ensure that patients have access to medically necessary items and services by making the Medicare local coverage determination (LCD) process more predictable and meaningful. -Support for the Ensuring Kids Have Access to Medically Necessary Dental Care Act (S 5088/HR 9833), which would strengthen dental coverage under the Childrens Health Insurance Program (CHIP) by prohibiting lifetime and annual dollar limits on dental benefits and requiring dental-only wraparound coverage for certain children.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Comments on the Reimagining and Improving Student Education Notice of Proposed Rulemaking; RIN 1840-AD98

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency.

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

Support for H.R. 879, the bipartisan Medicare Patient Access and Practice Stabilization Act, which would halt the 2.83 percent Medicare physician payment cut and provide a 6.62 percent update through the end of the year to address inflationary pressures. Support for including language in HR 1 to halt the current year cuts and provide long-term reform to the Medicare physician payment system. Concerns about medicaid-related provisions in HR 1.

Support for the extension of several small business tax reductions and opposition to the removal of the pass-through entity tax deduction in the One Big Beautiful Bill Act (HR 1)

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes. Opposing student loan reforms in the One Big Beautiful Bill Act (HR 1) -specifically the elimination of the Grad Plus Loan program, the implementation of federal loan caps and the prohibition of time spent in medical and dental residency from counting toward public service loan forgiveness (PSLF).

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees onnon-covered services Support for reintroduction of the Ensuring Lasting Smiles Act, which would require health insurers to cover treatment, including dental, for patientswith congenital craniofacial anomalies.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes. Opposing student loan reforms in the One Big Beautiful Bill Act (HR 1) -specifically the elimination of the Grad Plus Loan program, the implementation of federal loan caps and the prohibition of time spent in medical and dental residency from counting toward public service loan forgiveness (PSLF).

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Input to the Department of Education regarding implementation of student loan provisions from the One Big Beautiful Bill Act (OBBB). Concerns to the U.S. Department of Education regarding proposed rulemaking on the Public Service Loan Forgiveness (PSLF) program that seeks to bar organizations from participating in the PSLF program if they engage in activities that have a substantial illegal purpose.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes. Opposing student loan reforms in the One Big Beautiful Bill Act (HR 1) -specifically the elimination of the Grad Plus Loan program, the implementation of federal loan caps and the prohibition of time spent in medical and dental residency from counting toward public service loan forgiveness (PSLF).

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Suggestions for deregulation within federal healthcare programs, specifically the request to Rescind Limitations on Notice and Consent Waivers for Non-Emergency Services under the No Surprises Act and to Streamline or Eliminate the Merit-based Incentive Payment System (MIPS). Comments to CMS expressing concern about implementation of the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act as provided for in the CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Proposed Rule. Support for HR 4556, the the Protect Our Treatment for Enamel, Erosion, and Tooth Health (TEETH Act), which would require the Environmental Protection Agency (EPA) to commission an independent, rapid-response evidence review from the National Academies of Sciences, Engineering, and Medicine before proposing updates to drinking water regulations that affect community water fluoridation.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications and the Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP).

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Suggestions for deregulation within federal healthcare programs, specifically the request to Rescind Limitations on Notice and Consent Waivers for Non-Emergency Services under the No Surprises Act and to Streamline or Eliminate the Merit-based Incentive Payment System (MIPS). Comments to CMS expressing concern about implementation of the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act as provided for in the CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Proposed Rule. Support for HR 4556, the the Protect Our Treatment for Enamel, Erosion, and Tooth Health (TEETH Act), which would require the Environmental Protection Agency (EPA) to commission an independent, rapid-response evidence review from the National Academies of Sciences, Engineering, and Medicine before proposing updates to drinking water regulations that affect community water fluoridation.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications and the Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP).

Support for H.R. 879, the bipartisan Medicare Patient Access and Practice Stabilization Act, which would halt the 2.83 percent Medicare physician payment cut and provide a 6.62 percent update through the end of the year to address inflationary pressures.

Support for H.R. 879, the bipartisan Medicare Patient Access and Practice Stabilization Act, which would halt the 2.83 percent Medicare physician payment cut and provide a 6.62 percent update through the end of the year to address inflationary pressures.

Support for H.R. 879, the bipartisan Medicare Patient Access and Practice Stabilization Act, which would halt the 2.83 percent Medicare physician payment cut and provide a 6.62 percent update through the end of the year to address inflationary pressures. Support for including language in HR 1 to halt the current year cuts and provide long-term reform to the Medicare physician payment system. Concerns about medicaid-related provisions in HR 1.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1521), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act (S 1677/HR 3277), which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Suggestions for deregulation within federal healthcare programs, specifically the request to Rescind Limitations on Notice and Consent Waivers for Non-Emergency Services under the No Surprises Act and to Streamline or Eliminate the Merit-based Incentive Payment System (MIPS). Comments to CMS expressing concern about implementation of the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act as provided for in the CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Proposed Rule. Support for HR 4556, the the Protect Our Treatment for Enamel, Erosion, and Tooth Health (TEETH Act), which would require the Environmental Protection Agency (EPA) to commission an independent, rapid-response evidence review from the National Academies of Sciences, Engineering, and Medicine before proposing updates to drinking water regulations that affect community water fluoridation.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications and the Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP).

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Suggestions for deregulation within federal healthcare programs, specifically the request to Rescind Limitations on Notice and Consent Waivers for Non-Emergency Services under the No Surprises Act and to Streamline or Eliminate the Merit-based Incentive Payment System (MIPS). Comments to CMS expressing concern about implementation of the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act as provided for in the CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Proposed Rule. Support for HR 4556, the the Protect Our Treatment for Enamel, Erosion, and Tooth Health (TEETH Act), which would require the Environmental Protection Agency (EPA) to commission an independent, rapid-response evidence review from the National Academies of Sciences, Engineering, and Medicine before proposing updates to drinking water regulations that affect community water fluoridation.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications and the Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP).

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Input to the Department of Education regarding implementation of student loan provisions from the One Big Beautiful Bill Act (OBBB). Concerns to the U.S. Department of Education regarding proposed rulemaking on the Public Service Loan Forgiveness (PSLF) program that seeks to bar organizations from participating in the PSLF program if they engage in activities that have a substantial illegal purpose.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes.

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 1758, the Dental Loan Repayment Assistance Act, which would allow full-time dental faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes. Opposing student loan reforms in the One Big Beautiful Bill Act (HR 1) -specifically the elimination of the Grad Plus Loan program, the implementation of federal loan caps and the prohibition of time spent in medical and dental residency from counting toward public service loan forgiveness (PSLF).

Support for the Resident Education Deferred (REDI) Act (HR 2028/S 942), which would allow physicians and dentists to defer their student loans interest free during residency.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Suggestions for deregulation within federal healthcare programs, specifically the request to Rescind Limitations on Notice and Consent Waivers for Non-Emergency Services under the No Surprises Act and to Streamline or Eliminate the Merit-based Incentive Payment System (MIPS). Comments to CMS expressing concern about implementation of the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act as provided for in the CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Proposed Rule. Support for HR 4556, the the Protect Our Treatment for Enamel, Erosion, and Tooth Health (TEETH Act), which would require the Environmental Protection Agency (EPA) to commission an independent, rapid-response evidence review from the National Academies of Sciences, Engineering, and Medicine before proposing updates to drinking water regulations that affect community water fluoridation.

Support for the reintroduction of the following drug and supply bills from the 118th Congress: The RAPID Reserve Act, which aimed to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. The Mapping Americas Pharmaceutical Supply or MAPS Act, which sought to establish a comprehensive database to track the entire pharmaceutical supply chain. The Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the EPA to appeal a US District Four ruling in Food & Water Watch v EPA regarding water fluoridation.

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the DOD to maintain current water fluoridation levels on overseas bases. Suggestions for deregulation within federal healthcare programs. Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 1227/S. 475)

Support for the reintroduction of the following drug and supply bills from the 118th Congress: The RAPID Reserve Act, which aimed to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. The Mapping Americas Pharmaceutical Supply or MAPS Act, which sought to establish a comprehensive database to track the entire pharmaceutical supply chain. The Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 929/S. 266), which provides funding for programs that support mental healthcare for healthcare providers. Ask the EPA to appeal a US District Four ruling in Food & Water Watch v EPA regarding water fluoridation.

support for the Resident Education Deferred (REDI) Act (HR 1202/S 704), which would allow physicians and dentists to defer their student loans interest free during residency.

support for the Resident Education Deferred (REDI) Act (HR 1202/S 704), which would allow physicians and dentists to defer their student loans interest free during residency. Support for H.R. 7814, which would allow full-time faculty members participating in the Health Resources and Services Administrations (HRSA) Dental Faculty Loan Repayment Program (DFLRP) to exclude from income the amount of their loan forgiveness from their federal income taxes.

support for the Resident Education Deferred (REDI) Act (HR 1202/S 704), which would allow physicians and dentists to defer their student loans interest free during residency.

support for the Resident Education Deferred (REDI) Act (HR 1202/S 704), which would allow physicians and dentists to defer their student loans interest free during residency.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1385/S 1424), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act, which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1385/S 1424), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act, which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1385/S 1424), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act, which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for the Dental and Optometric Care (DOC) Access Act (HR 1385/S 1424), which would prohibit dental and vision plans from capping fees on non-covered services Support for reintroduction of the Ensuring Lasting Smiles Act, which would require health insurers to cover treatment, including dental, for patients with congenital craniofacial anomalies.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates and the Provider Reimbursement Stability Act (HR 6371) and Physician Fee Stabilization Act (S 4935), which would provide statutory changes to the budget neutrality requirement. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates and the Provider Reimbursement Stability Act (HR 6371) and Physician Fee Stabilization Act (S 4935), which would provide statutory changes to the budget neutrality requirement. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid. Comments to CMS re: use of American Dental Association (ADA) Dental Claim Form for Medicare covered dental services. Comments to CMS re: Dental Recommendations for CY 2025 Review Comments regarding the Medicaid Managed Care proposed rule and the Medicaid Equal Access Proposed Rule. Comments to CMS for CY 2025 ASC Covered Procedures List. Comments to CMS on dental codes for CY 2025 APC assignment.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid. Comments to CMS re: use of American Dental Association (ADA) Dental Claim Form for Medicare covered dental services. Comments to CMS re: Dental Recommendations for CY 2025 Review Comments regarding the Medicaid Managed Care proposed rule and the Medicaid Equal Access Proposed Rule. Comments to CMS for CY 2025 ASC Covered Procedures List. Comments to CMS on dental codes for CY 2025 APC assignment.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates and the Provider Reimbursement Stability Act (HR 6371) and Physician Fee Stabilization Act (S 4935), which would provide statutory changes to the budget neutrality requirement. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates and the Provider Reimbursement Stability Act (HR 6371) and Physician Fee Stabilization Act (S 4935), which would provide statutory changes to the budget neutrality requirement. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates and the Provider Reimbursement Stability Act (HR 6371) and Physician Fee Stabilization Act (S 4935), which would provide statutory changes to the budget neutrality requirement. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for Strengthening Medicare for Patients and Providers Act (HR 2474) which would reform the Medicare Physician Fee Schedule by creating annual inflationary updates and the Provider Reimbursement Stability Act (HR 6371) and Physician Fee Stabilization Act (S 4935), which would provide statutory changes to the budget neutrality requirement. Support for the Strengthening Medicaid Incentives for Licensees Enrolled in Dental (SMILED) Act (HR 1422), which would reduce administrative burdens for dentists who participate in Medicaid.

Support for the RAPID Reserve Act (S 1052/HR 6802) which would encourage domestic production of critical medicines and incentivize manufacturers to increase their reserves and ramp up production, when necessary, to proactively prevent shortages. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153/S. 3679), which provides funding for programs that support mental healthcare for healthcare providers.

Support for the RAPID Reserve Act (S 1052/HR 6802) which would encourage domestic production of critical medicines and incentivize manufacturers to increase their reserves and ramp up production, when necessary, to proactively prevent shortages. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153/S. 3679), which provides funding for programs that support mental healthcare for healthcare providers.

Support for the RAPID Reserve Act (S 1052/HR 6802) which would encourage domestic production of critical medicines and incentivize manufacturers to increase their reserves and ramp up production, when necessary, to proactively prevent shortages. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153/S. 3679), which provides funding for programs that support mental healthcare for healthcare providers. Concerns re: Tricare reimbursement for OMS procedures. Comments in response to the CY 2025 HOPPS/ASC proposed rule and Medicare Physician Fee Schedule proposed rule regarding coverage and payment for dental procedures.

Support for the RAPID Reserve Act (S 1052/HR 6802) which would encourage domestic production of critical medicines and incentivize manufacturers to increase their reserves and ramp up production, when necessary, to proactively prevent shortages. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153/S. 3679), which provides funding for programs that support mental healthcare for healthcare providers. Concerns re: Tricare reimbursement for OMS procedures. Communication to Senate HELP Committee re: dental access to care

Letter to Senate leaders in support of the small business tax policies included in the Tax Relief for American Families and Workers Act of 2024 (HR 7024)

Support for the Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act (H.R. 7142/S. 3832) to prevent unnecessary exposure to opioids and ensure access to the wide array of FDA-approved, safe, and effective non-opioid pain management approaches for Americas seniors.

Support for the RAPID Reserve Act (S 1052/HR 6802) which would encourage domestic production of critical medicines and incentivize manufacturers to increase their reserves and ramp up production, when necessary, to proactively prevent shortages. Support for legislation to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act (H.R. 7153/S. 3679), which provides funding for programs that support mental healthcare for healthcare providers. Concerns re: Tricare reimbursement for OMS procedures. Communication to Senate HELP Committee re: dental access to care